HilleVax, Inc. (NASDAQ:HLVX) Shares Sold by State Street Corp

State Street Corp decreased its position in shares of HilleVax, Inc. (NASDAQ:HLVX) by 1.6% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 585,795 shares of the company’s stock after selling 9,650 shares during the period. State Street Corp owned about 1.18% of HilleVax worth $1,031,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Maven Securities LTD acquired a new stake in shares of HilleVax during the second quarter worth about $217,000. BML Capital Management LLC acquired a new stake in HilleVax during the 3rd quarter worth approximately $35,000. Algert Global LLC purchased a new position in HilleVax in the 2nd quarter valued at approximately $519,000. Rhumbline Advisers grew its stake in shares of HilleVax by 27.0% in the second quarter. Rhumbline Advisers now owns 42,658 shares of the company’s stock worth $617,000 after acquiring an additional 9,073 shares in the last quarter. Finally, TD Asset Management Inc raised its stake in shares of HilleVax by 53.9% in the second quarter. TD Asset Management Inc now owns 54,236 shares of the company’s stock valued at $784,000 after acquiring an additional 19,000 shares in the last quarter. 86.42% of the stock is currently owned by hedge funds and other institutional investors.

HilleVax Price Performance

HLVX opened at $2.08 on Friday. The business has a fifty day moving average price of $1.91 and a 200 day moving average price of $3.08. HilleVax, Inc. has a 12 month low of $1.55 and a 12 month high of $20.22. The stock has a market capitalization of $103.60 million, a price-to-earnings ratio of -0.67 and a beta of 0.81.

HilleVax (NASDAQ:HLVX) last issued its earnings results on Thursday, November 7th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.42) by ($0.10). On average, research analysts anticipate that HilleVax, Inc. will post -2.64 earnings per share for the current year.

HilleVax Company Profile

HilleVax, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc and changed its name to HilleVax, Inc in February 2021.